Data Insights

MHB-088C by Minghui Pharmaceutical (Shanghai) for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Head And Neck Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

MHB-088C by Minghui Pharmaceutical (Shanghai) for Fallopian Tube Cancer: Likelihood of Approval

MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Fallopian Tube Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Fallopian Tube Cancer

Data Insights

MHB-088C by Minghui Pharmaceutical (Shanghai) for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC)....

Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

MHB-088C by Minghui Pharmaceutical (Shanghai) for Epithelial Ovarian Cancer: Likelihood of Approval

MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Epithelial Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Epithelial Ovarian Cancer

Data Insights

MHB-088C by Minghui Pharmaceutical (Shanghai) for Peritoneal Cancer: Likelihood of Approval

MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Peritoneal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Peritoneal Cancer

Data Insights

MHB-088C by Minghui Pharmaceutical (Shanghai) for Metastatic Ovarian Cancer: Likelihood of Approval

MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Metastatic Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Metastatic Ovarian Cancer

Data Insights

MHB-088C by Minghui Pharmaceutical (Shanghai) for Metastatic Colorectal Cancer: Likelihood of Approval

MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Metastatic Colorectal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Metastatic Colorectal Cancer

Data Insights

MHB-088C by Minghui Pharmaceutical (Shanghai) for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Pancreatic Ductal Adenocarcinoma

Data Insights

MHB-088C by Minghui Pharmaceutical (Shanghai) for Thyroid Cancer: Likelihood of Approval

MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Thyroid Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Thyroid Cancer

Data Insights

MHB-088C by Minghui Pharmaceutical (Shanghai) for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Metastatic Hepatocellular Carcinoma (HCC)

Data Insights

MHB-088C by Minghui Pharmaceutical (Shanghai) for Non-Small Cell Lung Cancer: Likelihood of Approval

MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Non-Small Cell Lung Cancer

Data Insights

MHB-088C by Minghui Pharmaceutical (Shanghai) for Endometrial Cancer: Likelihood of Approval

MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Endometrial Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Endometrial Cancer

Data Insights

MHB-088C by Minghui Pharmaceutical (Shanghai) for Solid Tumor: Likelihood of Approval

MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Solid Tumor. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Solid Tumor

Data Insights

MHB-088C by Minghui Pharmaceutical (Shanghai) for Sarcomas: Likelihood of Approval

MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Sarcomas. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Sarcomas

Data Insights

MHB-088C by Minghui Pharmaceutical (Shanghai) for Metastatic Melanoma: Likelihood of Approval

MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Metastatic Melanoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Metastatic Melanoma

Data Insights

MHB-088C by Minghui Pharmaceutical (Shanghai) for Small-Cell Lung Cancer: Likelihood of Approval

MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Small-Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Small-Cell Lung Cancer

Data Insights

MHB-088C by Minghui Pharmaceutical (Shanghai) for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC)....

Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Esophageal Squamous Cell Carcinoma (ESCC)